Key Takeaway: The PROSERA-EXT study aims to assess the long-term safety, tolerability, and efficacy of seralutinib in adults who have previously participated in seralutinib trials. This open-label extension provides an opportunity to gather additional data on the treatment's effects over an extended period. The study is listed on clinicaltrials.gov for further information.
Price reaction · baseline $0.8886 (2024-08-22T17:32:00.000Z) · hit during market hours · 1 other GOSS headline(s) in the window, move may be shared
day 0 close · peak
+0.3%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on long-term safety and efficacy of seralutinib.
Involvement of adult subjects enhances relevance.
Continuation from previous studies indicates promising results.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Full Press Release Details
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study.
PROSERA-EXT Study on clinicaltrials.gov Request More Information about PROSERA-EXT
Frequently Asked Questions
What is the purpose of the PROSERA-EXT study?
The study evaluates the long-term safety, tolerability, and efficacy of seralutinib.
Who are the participants in the study?
The study involves adult subjects who have completed a previous seralutinib study.
Where can I find more information about the study?
More information is available on clinicaltrials.gov.